Rafferty Asset Management’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.11M | Sell |
5,742
-3,145
| -35% | -$1.77M | 0.01% | 535 |
|
|
2026
Q1 | $5.27M | Sell |
8,887
-3,836
| -30% | -$1.91M | 0.02% | 344 |
|
|
2025
Q4 | $6.2M | Sell |
12,723
-8,359
| -40% | -$3.89M | 0.02% | 364 |
|
|
2025
Q3 | $8.84M | Sell |
21,082
-14,476
| -41% | -$4.87M | 0.03% | 306 |
|
|
2025
Q2 | $10.2M | Sell |
35,558
-404
| -1% | -$121K | 0.03% | 265 |
|
|
2025
Q1 | $11.1M | Sell |
35,962
-2,122
| -6% | -$727K | 0.05% | 246 |
|
|
2024
Q4 | $13.4M | Sell |
38,084
-12,872
| -25% | -$4.73M | 0.05% | 227 |
|
|
2024
Q3 | $18.3M | Sell |
50,956
-14,487
| -22% | -$4.89M | 0.06% | 158 |
|
|
2024
Q2 | $20.8M | Buy |
65,443
+27,713
| +73% | +$7.33M | 0.08% | 139 |
|
|
2024
Q1 | $8.67M | Buy |
37,730
+584
| +2% | +$132K | 0.03% | 319 |
|
|
2023
Q4 | $8.17M | Sell |
37,146
-2,378
| -6% | -$548K | 0.03% | 331 |
|
|
2023
Q3 | $8.93M | Buy |
39,524
+3,210
| +9% | +$739K | 0.05% | 251 |
|
|
2023
Q2 | $8.02M | Buy |
36,314
+6,523
| +22% | +$1.44M | 0.05% | 276 |
|
|
2023
Q1 | $6.67M | Buy |
29,791
+1,019
| +4% | +$251K | 0.05% | 309 |
|
|
2022
Q4 | $8M | Sell |
28,772
-2,282
| -7% | -$576K | 0.07% | 264 |
|
|
2022
Q3 | $6.5M | Buy |
31,054
+13,707
| +79% | +$3.06M | 0.07% | 249 |
|
|
2022
Q2 | $4.09M | Sell |
17,347
-13,563
| -44% | -$2.76M | 0.04% | 320 |
|
|
2022
Q1 | $5.55M | Buy |
30,910
+2,946
| +11% | +$561K | 0.03% | 365 |
|
|
2021
Q4 | $6.04M | Buy |
27,964
+13,146
| +89% | +$2.58M | 0.03% | 301 |
|
|
2021
Q3 | $2.73M | Buy |
14,818
+253
| +2% | +$49.8K | 0.02% | 533 |
|
|
2021
Q2 | $2.61M | Sell |
14,565
-6,312
| -30% | -$1.2M | 0.02% | 573 |
|
|
2021
Q1 | $3.49M | Buy |
20,877
+14,155
| +211% | +$2.36M | 0.02% | 391 |
|
|
2020
Q4 | $1.02M | Sell |
6,722
-12,633
| -65% | -$1.66M | 0.01% | 489 |
|
|
2020
Q3 | $1.96M | Buy |
19,355
+11,084
| +134% | +$1.22M | 0.02% | 423 |
|
|
2020
Q2 | $1M | Buy |
8,271
+3,127
| +61% | +$352K | 0.01% | 542 |
|
|
2020
Q1 | $488K | Sell |
5,144
-38,625
| -88% | -$3.67M | 0.02% | 333 |
|
|
2019
Q4 | $3.85M | Sell |
43,769
-36,553
| -46% | -$3.22M | 0.06% | 173 |
|
|
2019
Q3 | $6.41M | Buy |
80,322
+17,126
| +27% | +$1.38M | 0.1% | 118 |
|
|
2019
Q2 | $4.93M | Buy |
63,196
+17,735
| +39% | +$1.66M | 0.09% | 169 |
|
|
2019
Q1 | $5.34M | Buy |
+45,461
| New | +$5.3M | 0.09% | 126 |
|
|
2018
Q1 | – | Sell |
-27,456
| Closed | -$4.06M | – | 740 |
|
|
2017
Q4 | $4.06M | Buy |
+27,456
| New | +$3.49M | 0.07% | 146 |
|
|
2016
Q4 | – | Sell |
-5,174
| Closed | -$611K | – | 515 |
|
|
2016
Q3 | $611K | Sell |
5,174
-11,868
| -70% | -$1.43M | 0.02% | 319 |
|
|
2016
Q2 | $1.8M | Buy |
+17,042
| New | +$1.9M | 0.12% | 165 |
|
Other funds holding UTHR
ACA
JT
Rafferty Asset Management's UTHR Position: Q2 2026 in Review
Rafferty Asset Management reduced its United Therapeutics (UTHR) stake by 35% in Q2 2026, selling an estimated $1.77M and leaving 5,742 shares worth $3.11M. The position accounts for 0.01% of the portfolio, ranked #535.
Rafferty Asset Management first reported a position in UTHR in Q2 2016 and has held it in 33 quarters since. The position peaked at $20.8M in Q2 2024. 875 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.
- Rafferty Asset Management held 5,742 shares of United Therapeutics worth $3.11M as of Q2 2026.
- Rafferty Asset Management sold 3,145 United Therapeutics shares in Q2 2026, an estimated $1.77M.
- United Therapeutics made up 0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #535 holding.
- Rafferty Asset Management first reported a position in United Therapeutics in Q2 2016 and has held it in 33 quarters since.
- Rafferty Asset Management's United Therapeutics position peaked at $20.8M in Q2 2024.
- 875 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.
Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.